Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:28:14.527Z.
Calculation as of: 2026-10-06T17:28:14.527Z.
Quote observation: 2026-10-06T17:20:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24b9ae44b863bde1b5ff94dee696d3b0f0fe2fcb905e2d2ce235618745c02026
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$32.92M
EBITDA Yield
N/A
TTM Avg
0.01%
3Y Avg
0.01%
5Y Avg
0.01%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scilex Holding Company (SCLX) | $33.71M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $33.32M | N/A | 4.27% | 2.75% | 3.74% |
| HeartBeam, Inc. (BEAT)vs › | $33.25M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.17M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.04M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.92M | N/A | 0.01% | 0.01% | 0.01% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.66M | N/A | N/A | N/A | N/A |
| Rockwell Medical, Inc. (RMTI)vs › | $32.68M | N/A | 5.17% | 5.17% | 5.17% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.23M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 15.63% | 9.19% | 7.93% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
